STAT+: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more
Last week there was a change at the top of PhRMA, the trade group representing the drug industry. Novartis CEO Vas Narasimhan became the chair of the board of directors.
Narasimhan has been CEO of Novartis since 2018. He sat down with STAT to discuss the industry’s struggles in Washington, the future of Novartis, and whether the deflated biotech sector is still a little overvalued.
Continue to STAT+ to read the full story…
Narasimhan speaks during a conference at the Fortune Global Forum event in Paris
Information Courtesy By: Meg Tirrell and Adam Feuerstein and Damian Garde, #HealthcareNews #Healthcare | Feeds
Last week there was a change at the top of PhRMA, the trade group representing the drug industry. Novartis CEO Vas Narasimhan became the chair of the board of directors.
Narasimhan has been CEO of Novartis since 2018. He sat down with STAT to discuss the industry’s struggles in Washington, the future of Novartis, and whether the deflated biotech sector is still a little overvalued.
Continue to STAT+ to read the full story…
Narasimhan speaks during a conference at the Fortune Global Forum event in Paris
Click For More Details
2023-02-17 15:25
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.